Gradual dosing of Lilly drug for Alzheimer’s disease reduces risk of brain swelling
Starting a more gradual dosing schedule for Eli Lilly’s Alzheimer’s disease drug Kisunla reduces the percentage of patients suffering from potentially serious brain swelling, according to interim results from a late-stage study presented at a medical meeting Tuesday.
POPULAR POSTS
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVE STREAM